Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated her Overweight rating on LifeMD (NASDAQ:LFMD) and maintained a price target of $7.
September 14, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst has reiterated an Overweight rating on LifeMD and maintained a price target of $7.
The reiteration of an Overweight rating by a Cantor Fitzgerald analyst indicates a positive outlook for LifeMD. The maintained price target of $7 suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100